<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695652</url>
  </required_header>
  <id_info>
    <org_study_id>CT-COV-21</org_study_id>
    <nct_id>NCT04695652</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine&#xD;
      compared to placebo in participants who are generally healthy or with stable pre-existing&#xD;
      health conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, prospective, placebo-controlled, double-blinded (investigator/site staff&#xD;
      and participants), multi-center, multi-regional study; the Sponsor will be blinded until the&#xD;
      interim analysis. Participants who are generally healthy or with stable pre-existing health&#xD;
      conditions will be randomized, stratified by age (≥ 20 to &lt; 65 years and ≥ 65 years of&#xD;
      age).All eligible participants will be randomized to receive 2 doses of either MVC-COV1901 or&#xD;
      placebo in a predefined ratio.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Event within 28 days post the second study intervention (Safety of MVC-COV1901)</measure>
    <time_frame>Day 1 to 28 days after second vaccination</time_frame>
    <description>To evaluate the safety and tolerability of MVC-COV1901 from Visit 2 (Day 1) to Visit 7 (28 days after the second dose of study intervention) in terms of the number and percentage of participants with the occurrence of:&#xD;
Solicited local AEs (up to 7 days after each dose of study intervention)&#xD;
Solicited systemic AEs (up to 7 days after each dose of study intervention)&#xD;
Unsolicited AEs (up to 28 days after each dose of study intervention)&#xD;
AE of Special Interest (AESI)&#xD;
Vaccine-Associated Enhanced Disease(VAED)&#xD;
Serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of MVC-COV1901</measure>
    <time_frame>Day 1 to 14 days after second vaccination</time_frame>
    <description>To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of neutralizing antibody titers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Event throughout study conduct (Safety of MVC-COV1901)</measure>
    <time_frame>Day 1 to 180 days after second vaccination</time_frame>
    <description>To evaluate the safety of MVC-COV1901 over the study period in terms of the number and percentage of participants with the occurrence of:&#xD;
&gt;= Grade 3 AE&#xD;
AE of Special Interest (AESI)&#xD;
Vaccine-Associated Enhanced Disease(VAED)&#xD;
Serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lot to lot consistency</measure>
    <time_frame>Day 1 to 28 days after second vaccination</time_frame>
    <description>To evaluate the lot-to-lot consistency of MVC-COV1901 in participants of the ≥ 20 to &lt; 65 years age group, the equivalence of the neutralizing antibody Geometric Mean Titer(GMT) among 3 different lots of MVC-COV1901</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of confirmed COVID-19 cases (Efficacy of MVC-COV1901)</measure>
    <time_frame>Day 1 to 180 days after second vaccination</time_frame>
    <description>To estimate the efficacy of MVC-COV1901, as compared to placebo, in the prevention of COVID-19 in terms of :&#xD;
The number of laboratory-confirmed COVID-19 cases occurring ≥ 15 days after any dose of study intervention.&#xD;
The number of laboratory-confirmed COVID-19 severe cases occurring ≥ 15 days after any dose of study intervention.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Covid19 Vaccine</condition>
  <arm_group>
    <arm_group_label>MVC-COV1901(S protein with adjuvant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-2P protein with CpG and Aluminum Hydroxide/0.5mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVC-COV1901(Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline/0.5 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVC-COV1901(S protein with adjuvant)</intervention_name>
    <description>Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region</description>
    <arm_group_label>MVC-COV1901(S protein with adjuvant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVC-COV1901(Saline)</intervention_name>
    <description>Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region</description>
    <arm_group_label>MVC-COV1901(Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participant ≥ 20 to &lt; 65 years, or ≥ 65 years of age at randomization.&#xD;
&#xD;
          2. Healthy adults or adults with pre-existing medical conditions who are in stable&#xD;
             condition. A stable medical condition is defined as disease not requiring significant&#xD;
             change in therapy or hospitalization for worsening disease 3 months before enrollment&#xD;
             and expected to remain stable for the duration of the study.&#xD;
&#xD;
          3. Female participant must:&#xD;
&#xD;
               1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as&#xD;
                  having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral&#xD;
                  salpingectomy; tubal ligation alone is not considered sufficient) or one year&#xD;
                  post-menopausal;&#xD;
&#xD;
               2. Or, if of childbearing potential, be abstinent or agree to use medically&#xD;
                  effective contraception from 14 days before screening to 30 days following the&#xD;
                  last injection of study intervention. Acceptable forms include:&#xD;
&#xD;
             i. Implanted hormonal methods of contraception or placement of an intrauterine device&#xD;
             or intrauterine system ii. Established use of hormonal methods (injectable, pill,&#xD;
             patch or ring) combined with barrier methods of contraception: condom or occlusive cap&#xD;
             (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c.&#xD;
             Have a negative pregnancy test&#xD;
&#xD;
          4. Participant is willing and able to comply with all required study visits and follow-up&#xD;
             required by this protocol.&#xD;
&#xD;
          5. Participant has not travelled overseas within 14 days of screening and will not have&#xD;
             any oversea travelling throughout the study period.&#xD;
&#xD;
          6. Participant or the participant's legal representative must understand the procedures&#xD;
             of the study and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast feeding or have plan to become pregnant in 30 days after last&#xD;
             administration of study intervention.&#xD;
&#xD;
          2. Employees at the investigator's site, of the Sponsor or the contract research&#xD;
             organization (CRO) directly involved in the conduct of the study.&#xD;
&#xD;
          3. Currently receiving or received any investigational intervention within 30 days prior&#xD;
             to the first dose of study intervention.&#xD;
&#xD;
          4. Administered any licensed live-attenuated vaccines within 28 days or other licensed&#xD;
             non-live-attenuated vaccines within 7 days prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          5. Administered any blood product or intravenous immunoglobulin administration within 12&#xD;
             weeks prior to the first dose of study intervention.&#xD;
&#xD;
          6. Currently receiving or anticipate to receive concomitant immunosuppressive or&#xD;
             immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing&#xD;
             corticosteroids, low-dose methotrexate, or &lt; 2 weeks of daily receipt of prednisone&#xD;
             less than 20 mg or equivalent) within 12 weeks prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          7. Currently receiving or anticipate to receive treatment with tumor necrosis factor&#xD;
             (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to&#xD;
             the first dose of study intervention.&#xD;
&#xD;
          8. Major surgery or any radiation therapy within 12 weeks prior to the first dose of&#xD;
             study intervention Medical Conditions&#xD;
&#xD;
          9. Immunosuppressive illness or immunodeficient state, including hematologic malignancy,&#xD;
             history of solid organ, bone marrow transplantation, or asplenia.&#xD;
&#xD;
         10. A history of autoimmune disease (systemic lupus, rheumatoid arthritis, scleroderma,&#xD;
             polyarthritis, thyroiditis, Guillain-Barré syndrome, etc.).&#xD;
&#xD;
         11. A history of malignancy with potential risk for recurrence after curative treatment,&#xD;
             or current diagnosis of or treatment for cancer (exceptions are squamous and basal&#xD;
             cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
         12. Bleeding disorder considered a contraindication to intramuscular injection or&#xD;
             phlebotomy.&#xD;
&#xD;
         13. Human immunodeficiency virus (HIV) antibody positive participants with CD4 count &lt; 350&#xD;
             cells/mm3 or a detectable HIV viral load within the past year (low level variations&#xD;
             from 50-500 viral copies/mL or equivalent which do not lead to changes in&#xD;
             antiretroviral therapy [ART] are permitted).&#xD;
&#xD;
         14. Hepatitis B surface antigen (HBsAg) positive participant with positive hepatitis B e&#xD;
             antigen (HBeAg) or abnormal liver function.&#xD;
&#xD;
         15. Hepatitis C virus (HCV) antibody positive participants with detectable HCV ribonucleic&#xD;
             acid (RNA) viremia in recent 12 weeks.&#xD;
&#xD;
         16. Participant with ongoing acute diseases or serious medical conditions which will&#xD;
             interfere with adherence to study requirements, or the evaluation of any study&#xD;
             endpoint. Acute diseases or serious medical conditions include cardiovascular (e.g.&#xD;
             New York Heart Association Grade III or IV), pulmonary (e.g. chronic obstructive&#xD;
             pulmonary disease stage III or IV), hepatic (e.g. Child-Pugh Class C), neurologic&#xD;
             (e.g. dementia), metabolic (e.g. diabetes mellitus with hemoglobin A1c [HbA1c] &gt; 8%),&#xD;
             renal (Stage 3 or worse chronic kidney disease), psychiatric condition (e.g.&#xD;
             alcoholism, drug abuse), current severe infections, medical history, physical&#xD;
             findings, or laboratory abnormality that in the investigators' opinion are not in&#xD;
             stable condition and participating in the study could adversely affect the safety of&#xD;
             the participant.&#xD;
&#xD;
             Medigen Vaccine Biologics Corp. 34&#xD;
&#xD;
         17. Participant with previous known or potential exposure to SARS-CoV-1 or 2 viruses&#xD;
             (EXCEPT for those who have been tested negative and completed the 14-day&#xD;
             self-managements/ home quarantines/ home isolations) or received any other COVID-19&#xD;
             vaccine.&#xD;
&#xD;
         18. Participant with a history of hypersensitivity to any vaccine or a history of allergic&#xD;
             disease or reactions likely to be exacerbated by any component of the MVC-COV1901.&#xD;
&#xD;
         19. Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor&#xD;
             illnesses such as diarrhea or mild upper respiratory tract infection at the discretion&#xD;
             of the investigator) within 2 days before the first dose of study intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szu-Min Hsieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tzou-Yien Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gang Memorial Hospital, LinKou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Criss Cheng</last_name>
    <phone>+886277450830 ext 606</phone>
    <email>CrissCheng@medigenvac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard Cheng</last_name>
    <phone>+886277450830 ext 601</phone>
    <email>HowardCheng@medigenvac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu-Lin Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-Hsu Chen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kao-Pin Hwang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wen-Chien Ko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szu-Min Hsieh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Szu-Min Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Che Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Municipal Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Sen Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinn-Jang Hwang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning-Chi Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang-Guang Memorial Hospital Lin-Kou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsou-Yien Lin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tsou-Yien Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tao-Yuan General Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shu-Hsing Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Hygiene and Epidemiology</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vu Dinh Thiem, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19 vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatomedin B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

